Jubilee Post News & Views
Jubilee News Desk
Serum Institute of India (SII), world’s biggest vaccine maker, has applied for local trials for the vaccine candidate in India and is hopeful of launching Covovax by June.
SII CEO Adar Poonawalla said in a tweet on Saturday when its one year to India’s fight against the infection, “Our partnership for a COVID-19 vaccine with @Novavax has also published excellent efficacy results. We have also applied to start trials in India.
Hope to launch #COVOVAX by June 2021!” It has been developed in partnership with American vaccine developer Novavax.
The US-based pharma firm’s Covid jab was found to be 89.3 per cent effective in a UK trial. The Pune-based Serum Institute has already applied for local trials for the vaccine candidate in India.
Earlier this month, India began the world’s largest inoculation drive after the drug regulator DCGI cleared two vaccines – the SII’s Covishield and Hyderabad-based pharma firm Bharat Biotech’s Covaxin.
also read : Big decision for spouses of H-1B workers
also read : President Biden begins delivering on climate promises with Paris, Keystone
Covishield has been developed in partnership with the Oxford University and British-Swedish firm AstraZeneca. India is the fastest country in the world to vaccinate three million people, the government said in a series of tweets on Friday, drawing comparison with other nations.
The efficacy of the Novavax vaccine was calculated at 95.6 per cent against the original coronavirus strain, and 85.6 per cent against the UK variant. But the level of protection was lower in a smaller, mid-stage trial conducted in South Africa.
